ReviewBritish journal of clinical pharmacology2015
What do we learn from repeated population analyses?
Review in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Population pharmacokinetics of bedaquiline: a systematic review.European journal of clinical pharmacology · 2025Pooled it
- Significant Predictors of Azithromycin in Population Pharmacokinetic Analysis: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.European journal of clinical pharmacology · 2024Pooled it
- Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Clinical pharmacokinetics · 2017Trial
- Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.European journal of clinical pharmacology · 2015Trial
- A Comprehensive Analysis of Teicoplanin Population Pharmacokinetic Models in Pediatric Populations: Age-Dependent Variability and Implications for Dose Optimization.Infection and drug resistance · 2025Review
- Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients.Pharmaceutics · 2024Review
- Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban.Pharmaceutics · 2023Review
- Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.British journal of clinical pharmacology · 2022Review
- Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.Thrombosis research · 2021Article
- Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.Clinical pharmacokinetics · 2021Review
- How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective.European journal of drug metabolism and pharmacokinetics · 2020Review
- Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Antimicrobial agents and chemotherapy · 2016Article
- External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.British journal of clinical pharmacology · 2016Article
- Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.The AAPS journal · 2015Article
- Pharmacometrics: so much mathematics and why planes achieve their destinations with almost perfect results ….British journal of clinical pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population analyses are performed on new and existing drugs. They play an important role in quantifying the time course of drug effects and provide a means of understanding the impact of variability between individuals on dosing requirements. For some drugs there have been several population analyses reported in the literature. It is important to understand how repeated population analyses can value add and what authors and readers can consider when reviewing such analyses. The purpose of this review is to explore what is learnt from repeated population analyses and provide an understanding of how the value-added nature of these analyses can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.